Telehealth Firm Ro Partners With Eli Lilly to Boost Access to Obesity Drug Zepbound
Telehealth firm Ro has partnered with Eli Lilly And Co (NYSE:LLY) to enhance patient access to Zepbound (tirzepatide) single-dose vials for obesity treatment. Through LillyDirect, Ro will provide patients with streamlined access to this FDA-approved medication at a self-pay price,
Direct-to-consumer health and wellness company Ro will now offer access to lower-priced, single-dose vials of weight loss ...
It is made possible through a first-of-a-kind integration with Eli Lilly’s direct-to-consumer website, and aims to streamline ...
Eli Lilly strikes Zepbound deal with the telehealth platform Ro, amid questions about future of compounded GLP-1s.
By Sneha S K (Reuters) -Telehealth company Ro said on Wednesday it will offer single-dose vials of Eli Lilly's weight-loss ...
Eli Lilly is partnering with the Flatiron-based telehealth company Ro to sell a cheaper version of its popular weight-loss ...
"Offering Zepbound single-dose vials…through another platform to LillyDirect will help ensure broader availability of ...
Eli Lilly (LLY) has added a new telehealth partner to expand access to single-dose vials of its blockbuster weight loss drug ...
The partnership between Ro and Eli Lilly (LLY) to streamline access to Lilly’s GLP-1 Zepbound single-dose vials for Ro patients with obesity is ...
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning, hope everyone is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback